Skip to main content
SpringerLink
Log in

The Royal Marsden Hospital pilot tamoxifen chemoprevention trial

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

A pilot randomised placebo controlled trial using tamoxifen in healthy women at increased risk of developing breast cancer, has been undertaken in order to evaluate the problems of accrual, acute symptomatic toxicity, compliance, and safety as a basis for subsequent large national multicentre trials designed to test whether tamoxifen can chemoprevent breast cancer.

From October 1986 until June 1993, 2012 healthy women with an increased risk of developing breast cancer, usually because of a strong family history, were randomly allocated to receive tamoxifen 20 mgs/day or placebo for up to 8 years if possible.

Accrual remained high in spite of extensive informed consent regarding potential risk. Acute symptomatic toxicity was low for participants on tamoxifen or placebo and compliance remained correspondingly high with a predicted 77% of women on tamoxifen and 82% of women on placebo continuing medication at 5 years. There was a significant increase in hot flushes (34% versus 20%) mostly in premenopausal women (p < 0.005), vaginal discharge (16% versus 4%, p < 0.005), and menstrual irregularities (14% versus 9%, p < 0.005). The requirements for hormone replacement therapy for women on tamoxifen or placebo were the same.

Safety monitoring indicates no adverse anti oestrogenic effects of tamoxifen. There was no obvious effect of tamoxifen on bone mineral densities (single photon radial absorption). The fibrinogen and antithrombin III were both lowered, resulting in no observed detrimental effect on the ratio of these clotting factors. There was a significant reduction in the serum cholesterol maintained out to 5 years. Annual pelvic assessment using transvaginal ultrasound indicates an increased incidence of uterine fibromata and benign ovarian cysts. These results have encouraged the commencement of the NSABP national trial in the USA, and the subsequent start of national trials in Italy and the UK, which together should provide sufficient evidence to evaluate the efficacy of tamoxifen for prevention of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jordan VC: Effect of tamoxifen (ICI 46, 474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12: 419–424, 1976

    Google Scholar 

  2. Gottardis MM, Jordan VC: The antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47: 4020–24, 1987

    Google Scholar 

  3. Jordan VC, Lababidi MK, Langan-Fahey S: Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 83: 492–496, 1991

    Google Scholar 

  4. Ward HWC: Antioestrogen therapy for breast cancer. A trial of tamoxifen at low dose levels. Br Med J 1: 13–15, 1973

    Google Scholar 

  5. EBCTCG: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1–15, 71-85, 1992

    Google Scholar 

  6. Rutqvist LE, Cedermark B, Glas Uet al.: Contralateral primary tumours in breast cancer patients in a randomised trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 83: 1299–1306, 1991

    Google Scholar 

  7. Cuzick J, Wang DK, Bulbrook RD: The prevention of breast cancer. Lancet i: 83–86, 1986

    Google Scholar 

  8. Fugh-Berman A, Epstein S: Tamoxifen: disease prevention or disease substitution? Lancet 340: 1143–1145, 1992

    Google Scholar 

  9. Langan-Fahey SM, Tormey DC, Jordan VC: Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 26: 885–888, 1990

    Google Scholar 

  10. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, De Mets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852–856, 1992

    Google Scholar 

  11. Love RR, Newcomb PA, Wiebe D, Surawicz TS, Jordan VC, Carbone PP, De Mets DL: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82: 1327–1338, 1992

    Google Scholar 

  12. McDonald C, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Brit Med J 303: 435–437, 1991

    Google Scholar 

  13. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnett HD, Tillyer CR, Treleaven JG: A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60: 126–133, 1989

    Google Scholar 

  14. Powles TJ, Tillyer CR, Jones AL, Ashley SE, Treleaven J, Davey JB, McKinna JA: Prevention of breast cancer with tamoxifen - an update on the Royal Marsden pilot programme. Eur J Cancer 26: 680–684, 1990

    Google Scholar 

  15. Cuzick J: Protocol for the UKCCCR National Multicentre Tamoxifen Breast Cancer Prevention Trial. 1992

  16. Cohn JS, McNamara JR, Schaefer EJ: Lipoprotein and cholesterol concentrations in the plasma of human subjects as measured in the food and fasting status. Clin Chem 34: 2456–59, 1988

    Google Scholar 

  17. Bourne TH: Transvaginal color Doppler in gynaecology. Ultrasound Obstet Gynecol 1: 359–373, 1992

    Google Scholar 

  18. Dupont WD, Page DC: Menopausal estrogen replacement therapy and breast cancer. Arch Int Med 151: 67–73, 1991

    Google Scholar 

  19. Bush TL, Fried LP, Barrett-Connor E: Cholesterol lipoproteins and coronary heart disease in women. Clin Chem 34: B60–70, 1988

    Google Scholar 

  20. Rossner S, Wallgren A: Serum lipoproteins and protein after breast cancer surgery and effects of tamoxifen. Atherosclerosis 53: 339–346, 1984

    Google Scholar 

  21. Saphner T, Tomey DC, Gray R: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9: 286–294, 1991

    Google Scholar 

  22. Jones AL, Powles TJ, Treleaven J, Burman JF, Nicolson MC, Chung H-I, Ashley SE: Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. Brit J Cancer 66/4: 744–747, 1992

    Google Scholar 

  23. Fornander T, Rutqvist LE, Sjoberg HEet al.: Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 8: 1019–24, 1990

    Google Scholar 

  24. Fornander T, Cedermark B, Mattson Aet al.: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet i: 117–120, 1989

    Google Scholar 

  25. Van Leeuwen FE, Benraadt J, Coebergh JWet al.: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343: 448–452, 1994

    Google Scholar 

  26. Powles TJ and Ashley S. Endometrial cancer during tamoxifen treatment. Lancet 343: 978, 1994

    Google Scholar 

  27. Gerhard I, Runnebaum B: Comparison between tamoxifen and clomiphene therapy in women with anovulation. Arch Gynaecol 227: 279–288, 1979

    Google Scholar 

  28. Powles TJ: The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet 340: 1145–1147, 1992

    Google Scholar 

  29. Yagar JD, Shi YE: Synthetic oestrogens and tamoxifen as promotors of hepatocarcinogenesis. Preventive Medicine 20: 27–37, 1991

    Google Scholar 

  30. Han X, Liehr JG: Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Research 52: 1360–1363, 1992

    Google Scholar 

  31. Kaiser-Kupfer MI, Lippmann ME: Tamoxifen retinopathy. Cancer Treat Rep 62: 315–320, 1978

    Google Scholar 

  32. McKeown C, Swartz M, Blom J, Maggiano JM: Tamoxifen retinopathy. Brit J Ophthalmol 65: 177–179, 1981

    Google Scholar 

  33. Longstaff S, Sigurdsson H, O'Keeffe Met al.: A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur J Cancer Clin Oncol 25 (12): 1805–1808, 1989

    Google Scholar 

  34. Pavlidis N, Petris C, Briassoulis Eet al.: Clear evidence that long-term low-dose tamoxifen treatment can induce ocular toxicity. Cancer 69: 2961–2964, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Unit, Royal Marsden Hospital, London and Surrey, Downs Road, SM2 5PT, Sutton, Surrey, UK

    T. J. Powles, A. L. Jones, S. E. Ashley, M. E. R. O'Brien, V. A. Tidy, J. Treleavan, D. Cosgrove, A. G. Nash, N. Sacks, M. Baum, J. A. McKinna & J. B. Davey

Authors
  1. T. J. Powles
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. L. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. E. Ashley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. E. R. O'Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. A. Tidy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Treleavan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Cosgrove
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. G. Nash
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N. Sacks
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Baum
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J. A. McKinna
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J. B. Davey
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Powles, T.J., Jones, A.L., Ashley, S.E. et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Tr 31, 73–82 (1994). https://doi.org/10.1007/BF00689678

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00689678

Key words

Search

Navigation